LLY

818.58

+0.92%↑

JNJ

156.9

+0.22%↑

ABBV

190.58

-0.85%↓

NVO

79.74

-1.64%↓

UNH

313.25

-1.52%↓

LLY

818.58

+0.92%↑

JNJ

156.9

+0.22%↑

ABBV

190.58

-0.85%↓

NVO

79.74

-1.64%↓

UNH

313.25

-1.52%↓

LLY

818.58

+0.92%↑

JNJ

156.9

+0.22%↑

ABBV

190.58

-0.85%↓

NVO

79.74

-1.64%↓

UNH

313.25

-1.52%↓

LLY

818.58

+0.92%↑

JNJ

156.9

+0.22%↑

ABBV

190.58

-0.85%↓

NVO

79.74

-1.64%↓

UNH

313.25

-1.52%↓

LLY

818.58

+0.92%↑

JNJ

156.9

+0.22%↑

ABBV

190.58

-0.85%↓

NVO

79.74

-1.64%↓

UNH

313.25

-1.52%↓

Search

Coherus Biosciences Inc

Closed

SectorHealthcare

0.76 -3.8

Overview

Share price change

24h

Current

Min

0.75

Max

0.78

Key metrics

By Trading Economics

Income

-5.9M

-57M

Sales

-47M

7.6M

P/E

Sector Avg

1.942

51.748

EPS

-0.35

Profit margin

-744.427

Employees

221

EBITDA

115K

-44M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+535.44% upside

Dividends

By Dow Jones

Next Earnings

7 sie 2025

Market Stats

By TradingEconomics

Market Cap

-19M

99M

Previous open

4.56

Previous close

0.76

News Sentiment

By Acuity

50%

50%

172 / 380 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Weak Bearish Evidence

Coherus Biosciences Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

12 cze 2025, 20:41 UTC

Earnings

Adobe Raises Outlook After 2Q Sales Beat

12 cze 2025, 23:50 UTC

Earnings

Adobe Keeps Pivoting as AI Transforms Customer Needs -- Update

12 cze 2025, 23:50 UTC

Earnings

Adobe Customer Demand Shifting Toward Idea Generation, CFO Says

12 cze 2025, 23:50 UTC

Earnings

Adobe FireFly Products Drove Revenue Beat in 2Q, CFO Says

12 cze 2025, 23:48 UTC

Market Talk

Gold Steady Amid Geopolitical Risks -- Market Talk

12 cze 2025, 23:45 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

12 cze 2025, 23:45 UTC

Market Talk

Nikkei May Trade Rangebound Amid Tariff Uncertainty -- Market Talk

12 cze 2025, 21:26 UTC

Earnings

Friedman Industries 4Q Sales $129.2M >FRD

12 cze 2025, 21:25 UTC

Earnings

Friedman Industries 4Q EPS 76c >FRD

12 cze 2025, 21:11 UTC

Earnings

Adobe Beat Estimates and Raises Revenue Guidance -- Barrons.com

12 cze 2025, 20:50 UTC

Market Talk
Earnings

Tech, Media & Telecom Roundup: Market Talk

12 cze 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

12 cze 2025, 20:31 UTC

Earnings

Adobe Beat Estimates and Raises Revenue Guidance -- Barrons.com

12 cze 2025, 20:30 UTC

Earnings
Acquisitions, Mergers, Takeovers

Chime IPO: Stock Soars in Nasdaq Debut, Valuing It at Nearly $14 Billion -- Barrons.com

12 cze 2025, 20:15 UTC

Earnings

Adobe Sees FY25 Rev $23.5B-$23.6B >ADBE

12 cze 2025, 20:15 UTC

Earnings

Adobe Sees 3Q Rev $5.88B-$5.93B >ADBE

12 cze 2025, 20:14 UTC

Earnings

Adobe Stock Pops as Earnings Beat Estimates -- Barrons.com

12 cze 2025, 20:07 UTC

Earnings

Adobe Raises FY25 Rev and EPS Targets

12 cze 2025, 20:05 UTC

Earnings

Adobe Sees FY Adj EPS $20.50-Adj EPS $20.70 >ADBE

12 cze 2025, 20:05 UTC

Earnings

Adobe 2Q Digital Experience Revenue $1.46B >ADBE

12 cze 2025, 20:05 UTC

Earnings

Adobe 2Q Digital Media Revenue $4.35B >ADBE

12 cze 2025, 20:05 UTC

Earnings

Adobe Sees 3Q EPS $4.00-EPS $4.05 >ADBE

12 cze 2025, 20:05 UTC

Earnings

Adobe 2Q Net $1.69B >ADBE

12 cze 2025, 20:05 UTC

Earnings

Adobe 2Q EPS $3.94 >ADBE

12 cze 2025, 20:05 UTC

Earnings

Adobe 2Q Digital Experience Revenue Up 10% >ADBE

12 cze 2025, 20:05 UTC

Earnings

Adobe 2Q Rev $5.87B >ADBE

12 cze 2025, 20:05 UTC

Earnings

Adobe Sees 3Q Adj EPS $5.15-Adj EPS $5.20 >ADBE

12 cze 2025, 20:05 UTC

Earnings

Adobe Sees FY EPS $16.30-EPS $16.50 >ADBE

12 cze 2025, 20:05 UTC

Earnings

Adobe 2Q Digital Media Revenue Up 11% >ADBE

12 cze 2025, 20:05 UTC

Earnings

Adobe 2Q Adj EPS $5.06 >ADBE

Peer Comparison

Price change

Coherus Biosciences Inc Forecast

Price Target

By TipRanks

535.44% upside

12 Months Forecast

Average 5.02 USD  535.44%

High 7 USD

Low 1.05 USD

Based on 5 Wall Street analysts offering 12 month price targets forCoherus Biosciences Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

5 ratings

3

Buy

2

Hold

0

Sell

Technical Score

By Trading Central

0.9209 / 1.05Support & Resistance

Short Term

Weak Bearish Evidence

Intermediate Term

Weak Bullish Evidence

Long Term

Weak Bearish Evidence

Sentiment

By Acuity

172 / 380 Ranking in Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Coherus Biosciences Inc

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27. It is also developing CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody selectively targeting CCR8, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, an antibody targeting human ILT4 designed to improve anti-PD-1 clinical benefit by transforming an unfavorable TME to a more favorable TME. In addition, the company's licensed immuno-oncology programs include NZV930, an antibody designed to inhibit cluster of differentiation 73; and GSK4381562, an antibody targeting CD112R for the treatment of solid tumors. Further, it offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. It collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc., as well as Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.